Pollock, Jennifer S.

Abstract Aim We aimed to test the hypothesis that a high‐salt diet (HS) impairs NO signaling in kidney microvascular endothelial cells through a histone deacetylase 1 (HDAC1)‐dependent mechanism. Methods Male Sprague Dawley rats were fed normal salt diet (NS; 0.49% NaCl) or HS (4% NaCl) for 2 weeks. NO signaling was assessed by measuring L‐NAME induced vasoconstriction of the afferent arteriole using the blood perfused juxtamedullary nephron (JMN) preparation. In this preparation, kidneys were perfused with blood from a donor rat on a matching or different diet to that of the kidney donor. Kidney endothelial cells were isolated with magnetic activated cell sorting and HDAC1 activity was measured. Results We found HS‐induced impaired NO signaling in the afferent arteriole. This was restored by inhibition of HDAC1 with MS‐275. Consistent with these findings, HDAC1 activity was increased in kidney endothelial cells. We further found the loss of NO to be dependent upon the diet of the blood donor rather than the diet of the kidney donor and the plasma from HS‐fed rats to be sufficient to induce impaired NO signaling. This indicates the presence of a humoral factor we termed plasma‐derived endothelial dysfunction mediator (PDEM). Pretreatment with the antioxidants, PEG‐SOD and PEG‐catalase, as well as the NOS cofactor, tetrahydrobiopterin, restored NO signaling. Conclusion We conclude that HS activates endothelial HDAC1 through PDEM leading to decreased NO signaling. This study provides novel insights into the molecular mechanisms by which a HS decreases renal microvascular endothelial NO signaling.

High salt diet (HS) impairment of endothelial nitric oxide (NO) signaling has been described in human and rodents. The mechanisms which mediate this dysfunction remain unknown. We and others have previously shown histone deacetylase 1 (HDAC1) decreases endothelial NO production. We therefore sought to investigate the mechanisms by which HS initiates endothelial dysfunction and if it is HDAC1‐dependent. We first investigated if HS induced endothelial dysfunction is acutely regulated by a circulating factor. Male Sprague Dawley rats were fed normal salt diet (NS; 0.49% NaCl) or 2 weeks of HS (4.0% NaCl). Afferent arteriole vasoconstrictor responses to the NOS inhibitor, L‐NAME, were monitored using the in vitro, blood perfused juxtamedullary nephron preparation. Arterioles from HS fed rats perfused with blood from HS fed rats demonstrated blunted constriction to L‐NAME (96 ± 2% of Con) compared to arterioles from NS fed rats perfused with blood from NS fed rats (76.2 ± 2% of Con; P=0.0017). Perfusing arterioles from NS fed rats with blood HS fed rats blunted constriction to L‐NAME (88 ± 1% of Con) compared to perfusing with blood from NS fed rats (P=0.0003), but not to the same extent as arterioles from HS fed rats perfused with blood from HS fed rats (P=0.0095). HS arterioles perfused with blood from NS fed rats had similar L‐NAME‐induced constriction (75 ± 2% of Con) compared to arterioles from NS fed rats perfused with blood from NS fed rats (P=0.9107). In short, the impaired constriction to L‐NAME is dependent up on the diet of the blood donor and not the diet of the arteriole donor suggesting HS impairs endothelial function through an acute‐acting circulating factor. This was not due to increased plasma arginase activity (NS: 7.96 ± 3.73 U/L vs HS: 5.42 ± 1.83 U/L P=0.5813), changes in plasma tetrahydrobiopterin (NS: 65.09 ± 11.57 pmol/ml vs HS: 53.54 ± 5.59 pmol/ml, P=0.311) or changes in plasma dihydrobiopterin (NS: 98.18 ± 7.84 pmol/ml vs HS: 87.45 ± 13.28 pmol/ml, P=0.530). We then investigated if HS increased endothelial HDAC1 activity. Renal endothelial cells were isolated from NS and HS fed rats and incubated in plasma from the same rat. HDAC1 activity was defined as the MS‐275 (HDAC1 specific inhibitor) inhibitable portion of total HDAC activity. We found HS significantly increased renal endothelial HDAC1 activity (NS: 0.38 ± 0.03 pmol/min vs HS:0.94 ± 0.19 pmol/min, P=0.01). Furthermore, in vitro HDAC1 inhibition with 300 nM MS‐275 restored the arteriolar vasoconstrictor responses in HS rats (79 ± 3% of Con) to values similar to NS fed rats (P=0.969) and to NS rats + MS‐275 (79 ± 1% of Con; P>0.998). When plasma from HS fed rats was combined with erythrocytes from NS fed rats and perfused through arterioles from NS fed rats, constriction to L‐NAME was blunted (85 ± 3% of Con; P=0.0129). Under these same conditions, HDAC1 inhibition restored constriction (75.7 ± 0.95 % of Con) similar to controls (P=0.979). We conclude that HS disruption of renal microvascular NO signaling is initiated by a circulating factor(s) that increases endothelial HDAC1 activity.

We previously reported that small mesenteric arteries from hypertensive rats have increased NOS-derived H2O2 and reduced NO/cGMP signaling. We hypothesized that antihypertensive therapy lowers blood pressure through a tetrahydrobiopterin (BH4)-dependent mechanism restoring NO/cGMP signaling and endothelial NOS (NOS3; eNOS) phosphorylation in small arteries. To test this hypothesis, small mesenteric arteries from normotensive rats (NORM), angiotensin II-infused rats (ANG), ANG rats with triple therapy (reserperine, hydrochlorothiazide, and hydralazine), or ANG rats with oral BH4 therapy were studied. Both triple therapy and oral BH4 therapy attenuated the rise in systolic blood pressure in ANG rats and restored NO/cGMP signaling in small arteries similarly. Triple therapy significantly increased vascular BH4 levels and BH4-to-BH2 ratio similar to ANG rats with BH4 supplementation. Furthermore, triple therapy (but not oral BH4 therapy) significantly increased GTP cyclohydrolase I (GTPCH I) activity in small arteries without a change in expression. NOS3 phosphorylation at Ser1177 was reduced in small arteries from ANG compared with NORM, while NOS3 phosphorylation at Ser633 and Thr495 were similar in ANG and NORM. NOS3 phosphorylation at Ser1177 was restored with triple therapy or oral BH4 in ANG rats. In conclusion, antihypertensive therapy regulates NO/cGMP signaling in small arteries through increasing BH4 levels and NOS3 phosphorylation at Ser1177.